IDH1 and myelodysplastic syndrome: Similarly, the scrutiny of ivosidenib, a pharmaceutical agent developed for the treatment of relapsed or refractory myelodysplastic syndromes (MDS) characterized by IDH1 mutations [35], provides a compelling motivation for investigating metabolic rewiring mechanisms within diverse cancer types.